You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival
|
|---|---|
| Published in |
CardioVascular and Interventional Radiology, October 2016
|
| DOI | 10.1007/s00270-016-1478-z |
| Pubmed ID | |
| Authors |
James X. Chen, Steven Rose, Sarah B. White, Ghassan El-Haddad, Nicholas Fidelman, Hooman Yarmohammadi, Winifred Hwang, Daniel Y. Sze, Nishita Kothary, Kristen Stashek, E. Paul Wileyto, Riad Salem, David C. Metz, Michael C. Soulen |
| Abstract |
The purpose of the study was to evaluate prognostic factors for survival outcomes following embolotherapy for neuroendocrine tumor (NET) liver metastases. This was a multicenter retrospective study of 155 patients (60 years mean age, 57 % male) with NET liver metastases from pancreas (n = 71), gut (n = 68), lung (n = 8), or other/unknown (n = 8) primary sites treated with conventional transarterial chemoembolization (TACE, n = 50), transarterial radioembolization (TARE, n = 64), or transarterial embolization (TAE, n = 41) between 2004 and 2015. Patient-, tumor-, and treatment-related factors were evaluated for prognostic effect on hepatic progression-free survival (HPFS) and overall survival (OS) using unadjusted and propensity score-weighted univariate and multivariate Cox proportional hazards models. Median HPFS and OS were 18.5 and 125.1 months for G1 (n = 75), 12.2 and 33.9 months for G2 (n = 60), and 4.9 and 9.3 months for G3 tumors (n = 20), respectively (p < 0.05). Tumor burden >50 % hepatic volume demonstrated 5.5- and 26.8-month shorter median HPFS and OS, respectively, versus burden ≤50 % (p < 0.05). There were no significant differences in HPFS or OS between gut or pancreas primaries. In multivariate HPFS analysis, there were no significant differences among embolotherapy modalities. In multivariate OS analysis, TARE had a higher hazard ratio than TACE (unadjusted Cox model: HR 2.1, p = 0.02; propensity score adjusted model: HR 1.8, p = 0.11), while TAE did not differ significantly from TACE. Higher tumor grade and tumor burden prognosticated shorter HPFS and OS. TARE had a higher hazard ratio for OS than TACE. There were no significant differences in HPFS among embolotherapy modalities. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 8 | 57% |
| Greece | 1 | 7% |
| Brazil | 1 | 7% |
| Unknown | 4 | 29% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 6 | 43% |
| Members of the public | 6 | 43% |
| Scientists | 1 | 7% |
| Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 80 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 8 | 10% |
| Researcher | 8 | 10% |
| Professor > Associate Professor | 8 | 10% |
| Student > Master | 8 | 10% |
| Student > Bachelor | 7 | 9% |
| Other | 24 | 30% |
| Unknown | 17 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 53% |
| Nursing and Health Professions | 4 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Business, Management and Accounting | 1 | 1% |
| Mathematics | 1 | 1% |
| Other | 5 | 6% |
| Unknown | 24 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2019.
All research outputs
#2,680,760
of 22,893,031 outputs
Outputs from CardioVascular and Interventional Radiology
#105
of 2,375 outputs
Outputs of similar age
#47,736
of 319,487 outputs
Outputs of similar age from CardioVascular and Interventional Radiology
#1
of 43 outputs
Altmetric has tracked 22,893,031 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,375 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,487 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.